Objective-To assess the quality of medical care in childhood-onset systemic lupus erythematosus (cSLE) at tertiary pediatric rheumatology centers as measured by observance cSLE quality indicators (cSLE-QI).
Introduction
The Institute of Medicine defined quality as "the step to which health services for individuals and populations increase the probability of desired health consequences and are reliable with current specialized knowledge" (1) . Monitoring health care quality is virtually impossible without the use of so-called quality indicators (QI), i.e. minimum standards of medical care in support of optimal disease outcomes (2, 3).
Considering current medical knowledge and expert opinions, an international consensus has been reached for a set of 26 QI to be used for children and adolescents with childhood-onset systemic lupus erythematous (cSLE-QI) (4) . The cSLE-QI address laboratory testing at the time of cSLE diagnosis, general prevention, LN management, medication safety, bone health, ophthalmologic surveillance, education about cardiovascular risk factors, pregnancy, and neuropsychiatric manifestations (4) .
It has been shown in the past for many diseases that treatment at large centers may support the provision of medical care more reliably. Additionally, health disparity exists in pediatric rheumatology care. It has been suggested that this affects medical care for adult-onset SLE (5, 6) but it is unknown to which degree this affects basic cSLE medical care as can be defined by the cSLE-QI. As a next step towards focusing research and quality improvement efforts, benchmarking may help identify areas of health care that would benefit from added attention in an effort to improve patient outcomes.
Hence, the objective of this study was to measure the performance of the cSLE-QI in different regions of the world under consideration of differences in pediatric rheumatology center size. Furthermore, only for the U.S sites we aimed at delineating the effects of public and private insurance on the recommended medical care.
Materials and Methods
With the approval of institutional review boards of participating centers, cross-sectional population-based data pertaining to the cSLE-QI were acquired based on information provided in the medical records. A standardized data collection form (see supplemental table online) with detailed completion instructions were used to ensure consistent recording of events that only occur in quarterly or longer time intervals. The time frame for data collection was October 2011 through June 2014.
Patients and Participating Sites
Each center provided data on every cSLE patient seen more than once for cSLE care in the 12-month period preceding the data extraction. To be included in the study, patients had to fulfill Classification Criteria for SLE prior to the age of 18 years (7) . Pediatric rheumatology care at these centers was provided by physicians experienced and specifically trained in the care of children with rheumatic diseases. The seven centers participating in this study were self-selected.
Medical Record Review
Demographic information and insurance status were recorded. A QI item was only considered to be met if there was written documentation that a certain education or test had been performed. Information pertaining to cSLE-QI relevant to cSLE diagnosis was only obtained for patients diagnosed within 18 months of data collection. Furthermore, to have performed the cSLE-QI, any testing recommended at the time of cSLE diagnosis or that of LN diagnosis had to be documented in the medical record within two clinic visits of the index visit. LN flare was defined as worsening glomerular filtration rate or ongoing proteinuria. For performance of safety laboratory evaluations, we focused on glucocorticoid steroids (GCC) and hydroxychloroquine (HCQ). For the purpose of vaccination compliance, we only assessed performance of influenza vaccination. For life-style modification QI, we focused on smoking cessation (QI 24). Given the methodological approach taken, information about the diagnostic approach to suspected cSLE could not be assessed, as is considered in the first of the cSLE-QI.
Statistics
We performed descriptive analysis and calculated percent of QI implementation per center. We then assessed differences in cSLE-QI performance among U.S. centers, using CochranMantel-Haenzel test. Arbitrarily, centers treating at least 100 cSLE patients were considered as large and those following fewer cSLE patients as small, respectively. Differences between centers or categories of interest (large vs. small centers, U.S. private vs. public insurance) was assessed using contingency table analysis with a continuity-corrected Chisquare or a Fisher exact test, if appropriate. Two-sided probabilities were assessed and pvalues < 0.05 were considered statistically significant. Analyses were done with SAS 9.3 statistical software, published by SAS Institute Inc., Cary, NC, USA.
Results

Patients
A total of 483 patients followed at seven centers were included in this study ( Table 1 ). All seven sites were at academic centers, with three considered as large sites and four as small sites. All participating centers are at urban areas and all US sites have electronic medical record. There were 2-5 providers in the small centers and about 4-15 providers in large centers. Most patients were female. Notably, 178 patients from all of the sites were 18 years or older. Renal involvement in the cohorts ranged from 30% to 71%. Pregnancies were rare, and insurance status varied widely between sites, even in the same country.
Observance of the cSLE-QI by QI domain
Performance of the cSLE-QI is presented in the sequence previously published by Hollander et al. (4) .
Laboratory Testing at Diagnosis-The cSLE-QI (QI 2) recommended standard laboratory evaluation for children who newly carry the diagnosis of cSLE was documented for almost all patients (Table 2) .
General Prevention-The majority of the cSLE patients received the annual influenza vaccination (QI 3). However, there was a considerable variability among sites. This was also true for other cSLE-QI in this domain, namely education on sun avoidance, photoprotection, and transition planning (QI 4 -5).
Lupus Nephritis and Hypertension Management-Most of the sites followed the diagnostic procedures suggested for LN (QI 7 + 9). Exceptions were sites in Brazil with apparent problems with access to kidney biopsies. Regular laboratory surveillance for LN flares was performed inconsistently (QI 6 + 10), but immunosuppression for severe LN was started promptly at the majority of the sites (QI 8).
Medication Management-Explaining the risks and benefits of new medications for cSLE was regularly performed and documented (QI 13). Conversely, HCQ prescription varied between 75% to 100% at the participating sites (QI 14). Both GCC tapering efforts (QI 15) and high-dose GCC usage differed widely among the participating sites ( Table 1) . Introduction of immunosuppressive medications after failed GCC tapering (QI 16) was also highly variable (25 to 100%) but the number of patients per site available to assess the performance of this cSLE-QI was often small. However, sites generally performed the recommend safety laboratory testing with medication usage (QI 17).
Bone Health-Assessment of bone mineral density at least once in every patient with cSLE exposed to GCC differed widely among sites, ranging from 90% to 7% (QI 18). Lack of repetition of dual-energy x-ray absorptiometry (DEXA), when warranted, was congruent with the frequency of baseline DEXAs (QI 19). Calcium and Vitamin D supplementation with chronic GCC use also differed widely among sites (QI 20).
Ophthalmological Surveillance-Documentation of regular eye examination in the setting of HCQ and GCC use ranged from 96% to 72% of the patients at the participating sites (QI 21+ 22).
Education on Cardiovascular Risk Factors-The largest variability among sites was observed for education on cardiovascular risk factors and life style modification (QI 23+24).
Pregnancy and Neuropsychiatric cSLE-There were a few pregnancies, making the assessment of the observance of QI 25 difficult in this study. Immunosuppressive medication usage in the setting of major Neuropsychiatric Systemic Lupus Erythematosus (NPSLE) events was commonly done (QI 26). Table 3 presents cSLE-QI for which statistically significant differences in observance among the participating U.S. sites were observed. Among the 25 QIs assessed, there were 14 (14/25 = 56%) with important differences among the four U.S. sites. The largest variability was noted for QIs that address education on cardiovascular risks (QI 23 + 24) and calcium/ vitamin D supplementation with GCC use (QI 20).
Differences in Performance of the cSLE-QI in the U.S
Larger sites more consistently provide the recommended medical care to cSLE patients As is summarized in Table 4 , for 13 of the 25 QIs (13/25 = 52%) assessed there were statistical significant differences in observance between large (N=3) and smaller (N=4) sites. Generally, larger sites performed the QIs more frequently than smaller sites, with the exception of the recommended work-up at the time of LN diagnosis (QI 7).
Public vs. private health insurance in the U.S
Given known differences in the health insurance systems between countries, we only assessed whether there were differences in the quality of medical care by insurance status in the U.S. Besides rare patients without insurance, there were cSLE patients whose care was covered by private (n=189) and public insurance (n=112). There were no statistically significant differences in any of the cSLE-QI when compared by insurance groups.
Discussion
QI can be considered minimum standards of recommended medical care. In order to guide quality improvement efforts, benchmarking is required to delineate areas of greatest need for intervention. In a study of cSLE patients followed at tertiary rheumatology centers in the U.S., Brazil and India, we found statistically significant differences in the observance to cSLE-QI within the U.S. and also between larger and smaller centers.
Physicians across centers consistently ordered laboratory tests necessary in accordance to the two cSLE-QI addressing drug safety surveillance. Conversely, there was marked variation in the frequency patients of influenza vaccination. Given the increased risk of infections with cSLE, vaccinations are highly relevant for patient safety and disease control. Notably, there are documented suboptimal responses to at least some vaccinations with cSLE (8) . Therefore, cSLE patients should likely follow vaccination schedules that are recommended for immunocompromised populations. Potential barriers to vaccinations are a lack of affordability or reimbursement and potential deleterious effects of vaccine on disease itself. No severe vaccine or disease-specific adverse events have been observed in cSLE patients who have been vaccinated with non-live agents in a recent narrative review, reinforcing the vaccine safety for this population (9) . Possible approaches to improve vaccination rates include training of pediatricians and pediatric rheumatology providers about optimal vaccination practices. Additionally, education of families of children and young adults with cSLE about the benefits of vaccinations seems warranted.
It is well known that sun and other light exposure is associated with SLE disease flares (10) . Hence, photo protection education should be a critical part of care, but it was not consistently done at many of the participating centers.
Due to differences in the needs of children and adults with SLE, patients are transferred to adult providers generally after their 18 th birthday, although the exact age when the adult rheumatology commences care is influenced by many factors. Difficulties with transfer of care are supported by the findings of our study that a considerable proportion of cSLE patients age 18 or even 21 years and older continued to receive treatment at pediatric facilities. Transition planning seemed to constitute a challenge across all of the participating U.S. centers. Best transition practices are an intense focus of research and are influenced by not only patient factors but also health system factors (11). The former comprise patient selfmanagement skills and disease activity while the latter include access to adult providers, medications and required social support. Not all the sites have transition program in place. Both Brazilian centers have dedicated transition clinics for cSLE patients age 18 years or older with proven self-management skills.
The recommended work-up for LN, including a kidney biopsy, was well established across U.S. centers. Conversely, kidney biopsies were more difficult to obtain at the participating Brazilian sites. Time intervals at which patients with LN were assessed at the U.S. pediatric rheumatology centers were often longer than recommended, possibly suggesting problems with access to care.
In support of effective patient self-management, detailed discussion of risks and benefits of new medications is important and was generally provided by the physicians. The same held true for ordering the recommended laboratory testing for surveillance of drug safety. Antimalarial usage was provided to the vast majority of cSLE patients, with larger variability at non-U.S. sites. This may reflect difficulties in paying for such medications out of pocket. Likewise, tapering of high-dose GCC generally was attempted but, if unsuccessful, did not always result in prescribing GCC-sparing treatments. Reasons may be cost or lack of viable therapeutic alternatives.
Monitoring of bone health with chronic use of GCC varied widely across centers and was generally low in the U.S. and the participating site in India. This may expose patients to long-term risks associated with osteoporosis. This is a special concern as sites with low percentages of patients receiving monitoring of bone mineral density were also often not prescribing the recommended calcium/vitamin D prophylaxis. Further, even closer surveillance of patients with known low bone mineral density seems tenuous at best.
Often education on cardiovascular risk factors was not performed consistently. Reasons might include that cardiovascular events rarely occur while patients are under the care of pediatric rheumatologists. Education for cardiovascular risk factors and observance of some other cSLE-QI possibly may be better than the results we reported in our study since this is based strictly on information recorded in the medical records. In line with this, several centers indicated that the education referenced in these QI was provided but not systematically documented in the record.
We believe that inconsistent documentation is closely associated with inconsistent care across patient populations. Indeed, when we evaluated the QI 4 (education on sun-exposure) and considered education that was performed by physicians-to the best of their knowledgebut had not been documented in the medical record (data not shown), the observance of QI 4 increased up to 46% at some sites. Dedicated recording space in the electronic medical records improved documentation of all educational efforts. Lack of routine documentation of QI 4 was twice as common in small as compared to larger sites (23% vs. 12%) with marked variability at some sites.
As has been reported from other areas of medicine, we observed that larger centers more often reliably followed QI recommendations as compared to smaller centers. As such there were statistically significant differences in frequency at which 14 of the 25 QI examined in this study were followed, with smaller sites consistently showing lower endorsements. There was one exemption (QI 7) where larger sites performed worse than the smaller ones and this was due to limited access to kidney biopsies at the Brazilian sites.
While we found marked difference in QI performance among the tertiary U.S. pediatric rheumatology centers that participated in this study, similar standards of care were provided to patients with public as compared to private insurance. Thus health insurance status in the U.S. does not seem to influence minimum standards of care as is defined by the set of cSLEQIs.
Salient to the concept of quality indicators is the assumption that observance results in improved disease control and long-term prognosis. Our study did not collect information on disease activity or disease damage. Further no data are yet available in support of the notion that consistent observance of the cSLE-QI is associated with improved cSLE outcomes. Another limitation of the study is that there is a possibility of "volunteer" bias for the centers that participated or that the centers that participated may not be representative of all sites caring for cSLE patients. Among the seven participating sites in the study, two sites were involved in the initial development of the cSLE-QI. Nevertheless, our study remains the first to evaluate QI benchmarking among different international centers that care for cSLE patients, and can serve as the basis for further quality improvement work that has been largely lacking in cSLE.
Reasons for non-performance of QI is often multifactorial and the result of factors pertaining to patients and families, physicians and health care systems. Learning networks have been developed to address quality improvement approaches in complex, multi-center health care systems. An example from pediatric rheumatology may be PR-COIN (Pediatric Rheumatology Collaborative Improvement Network), a learning collaborative of 13 pediatric rheumatology sites, currently focused on juvenile arthritis care (12) . Within PR-COIN, patient education combined with improved disease monitoring and standards for adjusting therapies have led to a measurable increase in the children with remission. Similar efforts in cSLE seem necessary and beneficial to ensure improved evidence-based care of children with cSLE.
Significance and Innovations
• This constitutes the first benchmarking effort for the observance of the recently proposed cSLE quality indicators.
• Performance of some quality indicators differs significantly among pediatric rheumatology sites in the United States.
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